Compare iShares MSCI Hong Kong ETF (EWH) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs ResMed Inc. — how do they compare? iShares MSCI Hong Kong ETF trades at $22.03 (market cap $1.16B), while ResMed Inc. trades at $229.09 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 27.5× iShares MSCI Hong Kong ETF's market cap, and ResMed Inc. pays a 1.16% dividend while iShares MSCI Hong Kong ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and ResMed Inc. for 51 Days on average.
| EWH | RMD | |
|---|---|---|
Market Cap | $1.16B | $31.89B |
Volume | 3,176,523 | 618,314 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $277.88 |
52-Week Low | $20.66 | $182.82 |
Typical Hold Time | 61 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $21.58, down 0.19% today amid bearish technical signals with moving averages indicating strong selling pressure. The ETF tracks Hong Kong equities, which have faced volatility due to Federal Reserve policy and US-Iran tensions, as reflected in recent Hang Seng Index declines. Key support sits at $21 with resistance clustered around $22. Financial ratios are unavailable in the current dataset.
Outlook remains cautious given bearish technicals and macroeconomic headwinds impacting Hong Kong markets. Opportunities exist if geopolitical tensions ease and technology stocks rebound, but risks include prolonged Fed tightening and China economic struggles. Investors should monitor Hang Seng Index momentum and institutional flow trends for directional cues.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
